查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1847723

氣喘藥物市場按產品類型、藥物類別、通路、給藥途徑和最終用戶分類－2025-2032 年全球預測

Asthma Therapeutics Market by Product Type, Drug Class, Distribution Channel, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年氣喘藥物市場規模將成長至 626.7 億美元，複合年成長率為 10.96%。

主要市場統計數據
基準年2024年 272.6億美元
預計2025年 303.2億美元
預測年份：2032年 626.7億美元
複合年成長率（%） 10.96%

重塑氣喘藥物和病患照護途徑的臨床、監管和商業性力量融合的簡明框架

氣喘藥物領域正進入一個新階段，臨床創新、設備革新和醫療保健系統的壓力正在匯聚，重新定義針對各年齡層患者的醫療服務。生物製藥的進步治療方法改變重度、未控制氣喘的治療模式，吸入器和霧化器技術的不斷改進也持續影響常規治療。同時，支付方和醫療保健提供者要求提供現實世界療效和成本效益的明確證據，這迫使製造商重新思考其商業化和證據產生策略。

因此，相關人員必須在科學突破與實際運作之間找到平衡。監管途徑正在發生變化，以適應新型生物製藥和組合藥物藥物，供應鏈也在適應影響原料採購和生產佈局的地緣政治和貿易動態。如今，臨床醫生和看護者期待將治療手段與增強依從性的設備和數位監控相結合的綜合解決方案。

本引言概述了影響治療方法選擇、設備採用和相關人員行為的核心動態。它強調了創新、報銷和提供者工作流程之間的相互作用如何決定競爭優勢，為深入分析本報告中涵蓋的轉型變化、資費影響、細分考慮和區域洞察奠定了基礎。

深入探討生技藥品、設備融合、付款人需求和不斷變化的法規如何改變氣喘治療和商業化

氣喘藥物領域正在經歷一場變革，其驅動力來自治療方法專業化、設備整合、支付方審查以及數位化賦能。針對特定免疫途徑的生物製藥正從小眾用途轉向重症氣喘管理的核心角色，這迫使護理團隊採用依賴生物標記檢測和專科轉診網路的精準醫療方法。同時，吸入器和霧化器技術改進了劑量和易用性，鼓勵長期堅持用藥，並結合患者教育舉措，減少了急性護理事件。

同時，付款人和醫療保健系統要求更強力的價值敘述，這迫使他們展示超越傳統臨床終點的療效。這加速了真實世界證據和衛生經濟分析作為打入市場策略核心要素的應用。此外，設備和治療方法的融合正在催生新的商業模式，其中藥物-設備組合和數位化依從性平台是差異化因素。將吸入式設備與連網監測工具結合的製造商可以改善臨床療效，同時透過提供服務創造新的收益來源。

最後，監管機構正在重新調整核准和上市後預期，以適應組合藥物和生物製藥日益複雜的現狀。這些監管變革，加上對以病人為中心的醫療服務的日益重視，正在重塑商業性時間表和臨床開發方法。最終結果是，市場將鼓勵跨學科創新、協作證據產生和敏捷的商業化策略。

全面分析美國2025 年關稅格局及其對製造選擇、供應彈性和商業策略的下游影響。

美國將於2025年生效的新關稅和貿易措施，要求對整個氣喘藥物生態系統進行策略性評估，其累積影響取決於產品複雜性和供應鏈依賴程度。依賴進口零件、專用輔料和成品的企業正因投入成本上升而面臨利潤壓力，迫使它們重新協商供應商合約。生技藥品製造商通常依賴複雜、高價值的供應鏈和低溫運輸物流，因此尤其面臨風險，因為生產連續性和品管至關重要，且難以輕易轉移。

同時，專業醫療設備製造商受到獎勵，加快在岸化生產並實現零件採購多元化，以緩解關稅造成的成本波動。這一趨勢推動了對國內製造產能的投資增加、與合約開發和製造機構的合作以及流程自動化，以降低勞動強度。付款人和採購團隊對此作出了回應，他們收緊了處方標準，並加強了成本控制談判，迫使製造商提供更有力的比較有效性證據，並考慮創新定價。

貿易措施也影響了核准提交和上市時間，這對擁有垂直整合供應鏈和健全緊急時應對計畫的公司有利。因此，這些公司的策略性應對措施包括加速本地生產、重新設計包裝和零件採購以避免關稅分類，以及建立策略聯盟以共用製造風險。這些措施有助於保持競爭優勢，同時確保臨床醫生和患者的藥品供應連續性。

整合按產品類型、藥品類別、分銷管道、給藥途徑和最終用戶群體進行的詳細細分，以指導策略定位

準確的細分視角對於了解臨床價值和機會在產品類型、給藥途徑、分銷管道、藥物類別和最終用戶群之間的交集至關重要。根據產品類型，我們將生物製藥，生物製藥將乾粉、定量和緩霧吸入器嗜酸性粒細胞，每種吸入器都提供不同的性能特徵和依從性。霧化器細分為噴射式、網狀式和超音波霧化器，易用性、粒度控制和便攜性決定了臨床應用。口服藥物包括白三烯調節劑、口服類固醇和茶鹼，每種藥物根據嚴重程度、合併症情況和耐受性考慮佔據特定的市場。

依藥物類別細分，透過區分BETA受體促效劑、聯合治療、吸入性皮質類固醇、白三烯調節劑和單株抗體，進一步明確了治療選擇的促進因素。每個類別都與特定的疾病嚴重程度和指南建議一致，影響處方模式和處方放置。分銷管道細分揭示了醫生辦公室、醫院藥房、網路藥房和零售藥房之間在獲取藥物和病患體驗方面的差異。醫生辦公室類別包括居家照護機構和門診診所，它們的給藥模式和報銷途徑有顯著不同。給藥途徑細分捕獲了吸入、口服和腸外途徑之間的臨床和後勤權衡，其中吸入分為氣霧劑和粉劑，口服靜脈注射和皮下途徑，影響臨床醫生的參與、監測要求和患者偏好。

終端用戶細分將人口統計需求分為成人、老年人和兒童。老年人群進一步細分為65-74歲和75歲以上，以適應功能性用藥和多種藥物治療的需求；而兒童人群則細分為0-5歲和6-12歲，以適應設備適用性、劑量限制和看護者支持需求的差異。結合這些細分觀點，可以更細緻地觀點產品定位、臨床試驗設計、報銷策略和市場執行情況，並使其與實際治療途徑和相關人員的期望一致。

有關美洲、歐洲、中東和非洲以及亞太地區的市場准入、監管複雜性和採用動態的區域資訊

美洲、歐洲、中東和非洲以及亞太地區的區域動態正在影響產品開發、監管策略和商業化重點。在美洲，先進的專科護理網路和生物製藥支撐了重症氣喘的快速成長，但日益成長的支付方成熟度和成本控制壓力需要強力的衛生經濟證據和戰略性合約。因此，優先考慮美洲市場的製造商越來越重視療效數據、專科藥房合作夥伴關係以及減少行政摩擦和提高依從性的患者支援模式。

歐洲、中東和非洲地區法規和付款人制度各異，因此市場准入計畫必須考慮到各國醫療技術評估 (HTA) 流程、採購架構和報銷標準的差異。在這些市場營運的製造商通常會建立本地臨床註冊庫和真實世界證據項目，以證明其在當地環境下的價值，同時投資於適應競標和參考定價機制的定價策略。部分地區產能受限，可能需要建立更強大的經銷夥伴並開展培訓項目，以確保器械的妥善處理和管理。

亞太地區呈現出多元化的格局，快速的醫療現代化與不穩定的基礎設施和可近性並存。在某些市場，大規模學名藥製造商和不斷發展的生物技術產業帶來了激烈的競爭；而在其他市場，不斷擴展的診斷能力和專科護理正在推動對先進療法的需求。瞄準亞太地區的開發商通常會在密集的臨床開發與本地化的監管要求之間取得平衡，探索分階段的產品供應和本地化製造地，以控制成本並縮短前置作業時間。在所有地區，本地化的病人參與和臨床醫生教育仍然是成功實施的關鍵。

創新者、設備專家、非專利供應商和製造合作夥伴的策略競爭概述，塑造產品差異化和市場進入

氣喘治療領域的競爭態勢體現在創新生物製藥開發商、傳統吸入器和霧化器製造商、學名藥和口服藥物供應商以及新興設備技術參與企業之間的互補作用。專注於單株抗體的創新者正透過生物標記主導的適應症、生命週期策略以及向表現型特異性人群的擴展來推動差異化發展。這些公司也投資於伴隨診斷和專業通路，以最佳化患者選擇和依從性。

設備製造商持續在交付能力、用戶人體工學以及與數位依從性平台的整合方面展開競爭，並與製藥公司夥伴關係，提供差異化的藥械組合。學名藥和口服藥物製造商注重成本效益和廣泛的可用性，經常利用龐大的製造和分銷網路為基層醫療管道提供服務。同時，合約開發和受託製造廠商以及設備組件供應商是關鍵的推動者，他們提供的產能和技術專長會影響產品上市速度和在岸營運的可行性。

整體而言，公司策略強調盡可能進行垂直整合，建立策略聯盟以補充核心競爭力，並進行有針對性的收購以確保設備專業知識和生物製劑產品線。將臨床創新與強大的商業性執行力、證據產生能力和供應鏈韌性相結合的公司，能夠更好地規避付款方審查，並充分利用不斷變化的臨床指南和患者期望。

製造商需要採取切實可行的策略措施，協調臨床證據、設備整合、供應彈性和市場進入，以獲得競爭優勢

產業領導者應採取一系列切實可行的策略，將臨床價值與營運韌性和商業性敏捷性結合。首先，優先考慮證據生成，包括真實世界數據和患者報告結果，而不僅僅是隨機試驗。其次，在開發早期整合設備和數位化能力，創建配套服務模式，以提高依從性，提供可操作的患者數據，並佔據高階市場。

第三，透過地理多元化、策略性製造外包以及在關稅和物流風險不可接受的情況下選擇性地在岸外包，最佳化您的供應鏈。透過立即重新規劃您的採購和製造佈局，企業可以降低貿易波動帶來的脆弱性，並維持產品上市計畫。第四，透過投資衛生經濟學、成果研究和當地相關人員的參與，制定適合當地監管和報銷環境的打入市場策略。

最後，我們將尋求有針對性的合作，包括共同開發、授權和商業聯盟，以利用生技藥品、設備工程、數位健康等領域的互補能力。此類夥伴關係可加速市場進入，共用開發風險，並擴大治療生態系統。實施這些建議需要跨職能管治、明確的關鍵績效指標 (KPI) 和增量投資，以使研發、商業和製造目標與不斷變化的市場現實保持一致。

透過結合臨床專家訪談、二手文獻綜合、供應鏈映射和情境分析的嚴格混合方法研究途徑獲得可靠的見解

本分析整合了原始研究和二手研究，旨在為策略決策提供可靠且檢驗的依證。原始研究包括與呼吸系統醫療設備和過敏科臨床關鍵意見領袖進行結構化諮詢、與各治療和器械領域的商業高管進行訪談，以及與採購和付款人代表進行諮詢，以了解報銷優先級和簽約趨勢。這些調查提供了關於臨床醫生偏好、患者依從性促進因素以及商業性決策框架的定性見解。

二次調查全面回顧了同行評審的臨床文獻、監管指南文件以及描述治療機制、設備性能特徵和安全注意事項的行業出版物。供應鏈圖譜和資費分類分析確定了薄弱環節，並評估了潛在的緩解策略。對觀察結果和次要研究觀察進行三角檢驗，確保了臨床、商業和營運方面的一致性。

分析方法包括比較產品定位分析、針對關稅和供應鏈中斷的情境規劃，以及細分主導的評估，以確保產品屬性與最終用戶和分銷管道的需求相符。品管方法包括訪談結果的交叉檢驗、監管和臨床文獻的資訊來源檢驗，以及用於完善結論的迭代同行評審。這些方法的結合，為規劃產品開發、市場准入和策略投資的相關人員提供了令人信服且切實可行的見解。

執行總結強調了對綜合臨床證據、設備創新、彈性供應鏈和客製化存取策略的需求

總而言之，氣喘治療領域蘊藏著一系列複雜且易於掌握的機遇，而這得益於臨床創新與務實的商業和營運策略的結合。生物製藥正在重新定義嚴重表現型患者的治療，而設備和數位化技術的進步則正在提高依從性並支持新的基於價值的模式。然而，諸如付款人審查和貿易相關關稅變化等外部壓力要求我們在證據生成、供應鏈設計和定價策略方面做出適應性應對。

成功的相關人員能夠整合跨學科能力，例如開發強大的真實世界證據專案、以使用者為中心的設備設計以及建立富有彈性的製造佈局。投資夥伴關係，無論是與設備工程師、契約製造或區域經銷商，都能加速市場進入並降低執行風險。此外，根據當地監管和報銷情況制定策略，可以提升不同市場的可及性和商業性績效。

這項結論強調，研發、商業和營運團隊必須齊心協力，將科學進步轉化為永續的病患效益和商業性回報。那些積極主動地重視證據、整合和韌性的組織，將最有能力引領不斷發展的氣喘治療生態系統。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 標籤擴展後生物製劑治療重度嗜酸性粒細胞氣喘的長期安全性和有效性的真實世界證據
  • 將數位吸入器與遠端醫療平台結合，可提高兒童和成人氣喘患者的用藥依從性和監測能力
  • 開發小分子 CRTh2 受體拮抗劑作為治療中度至重度氣喘的新型口服治療藥物
  • 探索個人化氣喘治療流程，結合基因組和生物標記分析數據來選擇生物目標
  • ICS、LABA 和 LAMA 三聯吸入器療法在改善未控制氣喘患者控制方面的進展
  • FDA 和 EMA 近期擴大 tezepelumab 和 dupilumab 的適應症範圍對全球氣喘治療策略的監管影響
  • 抗 TSLP 和抗 IL-25 候選藥物的出現及其重新定義重度氣喘治療方案的潛力

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章氣喘藥物市場（依產品類型）

  • 生物製藥
    • 抗IgE
    • 抗IL5
  • 吸入器
    • 乾粉吸入器
    • 定量噴霧吸入器
    • 緩霧吸入器
  • 噴霧器
    • 噴射霧化器
    • 網狀霧化器
    • 超音波霧化器
  • 口服藥物
    • 白三烯調節劑
    • 口服類固醇
    • 茶鹼

第9章氣喘藥物市場（依藥物類別）

  • BETA-促效劑
  • 聯合治療
  • 吸入性皮質類固醇
  • 白三烯調節劑
  • 單株抗體

第 10 章氣喘藥物市場（依分銷管道）

  • 診所
    • 居家照護環境
    • 門診
  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 11 章氣喘藥物市場（依給藥途徑）

  • 吸入
    • 氣霧劑
    • 粉末
  • 口服
    • 糖漿狀
    • 藥片
  • 腸外
    • 靜脈
    • 皮下

第 12 章氣喘藥物市場（依最終使用者）

  • 成人
  • 老年人
    • 65-74歲
    • 75歲或以上
  • 孩子們
    • 0至5歲
    • 6至12歲

第13章氣喘藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章氣喘藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各國氣喘藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • GlaxoSmithKline plc
    • AstraZeneca PLC
    • Teva Pharmaceutical Industries Limited
    • Novartis AG
    • Sanofi SA
    • Boehringer Ingelheim International GmbH
    • Viatris Inc.
    • Sunovion Pharmaceuticals Inc.
    • Chiesi Farmaceutici SpA
    • Cipla Limited
Product Code: MRR-AB49FC1AB810

The Asthma Therapeutics Market is projected to grow by USD 62.67 billion at a CAGR of 10.96% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 27.26 billion
Estimated Year [2025] USD 30.32 billion
Forecast Year [2032] USD 62.67 billion
CAGR (%) 10.96%

A concise framing of the converging clinical, regulatory, and commercial forces reshaping asthma therapeutics and patient care pathways

The asthma therapeutics environment is entering a phase where clinical innovation, device evolution, and health system pressures converge to redefine care delivery for patients across age groups. Advances in biologic therapies have shifted treatment paradigms for severe and uncontrolled asthma, while incremental improvements in inhaler and nebulizer technology continue to shape everyday management. At the same time, payers and providers are demanding clearer evidence of real-world effectiveness and cost utility, prompting manufacturers to rethink commercialization and evidence-generation strategies.

As a result, stakeholders must navigate a landscape that balances scientific breakthroughs with operational realities. Regulatory pathways are adapting to accommodate novel biologic modalities and combination products, and supply chains are adjusting to geopolitical and trade dynamics that affect component sourcing and manufacturing footprints. Clinicians and caregivers now expect integrated solutions that couple therapeutics with adherence-enhancing devices and digital monitoring, which in turn forces manufacturers to develop cross-functional capabilities in product development, data analytics, and patient support programs.

This introduction frames the core dynamics influencing therapy selection, device adoption, and stakeholder behavior. It clarifies how the interplay between innovation, reimbursement, and provider workflows will determine competitive advantage, and sets the stage for deeper analysis of transformative shifts, tariff impacts, segmentation insights, and regional considerations included in this report.

Detailed exploration of how biologics, device convergence, payer demands, and regulatory evolution are collectively transforming asthma care and commercialization

The landscape for asthma therapeutics is undergoing transformative shifts driven by therapeutic specialization, device integration, payer scrutiny, and digital augmentation. Biologic therapies targeting specific immunological pathways have moved from niche applications to central roles in the management of severe asthma, compelling care teams to adopt precision medicine approaches that rely on biomarker testing and specialist referral networks. Concurrently, inhaler and nebulizer technologies have improved dose delivery and usability, encouraging longer-term adherence and reducing acute care episodes when paired with patient education initiatives.

In parallel, payers and health systems are demanding stronger value narratives, creating pressure to demonstrate outcomes beyond traditional clinical endpoints. This has accelerated the use of real-world evidence and health economics analyses as core components of market access strategies. Moreover, device-therapy convergence is fostering new commercial models where drug-device combinations and digital adherence platforms become differentiators. Manufacturers that integrate inhalation devices with connected monitoring tools stand to improve clinical outcomes while creating new revenue streams through service offerings.

Finally, regulatory agencies are recalibrating approval and post-market surveillance expectations to match the complexity of combination products and biologics. This regulatory evolution, combined with an emphasis on patient-centric care, is reshaping commercial timelines and clinical development approaches. The net effect is a market that rewards cross-disciplinary innovation, collaborative evidence generation, and nimble commercialization strategies.

Comprehensive analysis of the United States 2025 tariff landscape and its downstream effects on manufacturing choices, supply resilience, and commercial strategies

The introduction of new tariffs and trade measures in the United States in 2025 has prompted a strategic reassessment across the asthma therapeutics ecosystem, with cumulative impacts that vary by product complexity and supply chain dependence. Companies that rely on imported components, specialized excipients, or finished devices have experienced escalated input costs that compress margins and prompt renegotiation of supplier contracts. Manufacturers of biologics, which often depend on complex, high-value supply chains and cold-chain logistics, face particular exposure because production continuity and quality control are critical and not easily relocated.

On the other hand, device-focused producers have had incentives to accelerate onshoring or diversify component sourcing to mitigate tariff-driven cost volatility. This trend has driven increased investment in domestic manufacturing capacity, contract development and manufacturing organization partnerships, and process automation to reduce labor intensity. Payers and procurement teams have responded by tightening formulary criteria and intensifying cost-containment negotiations, which pressures manufacturers to present stronger evidence of comparative effectiveness and to consider innovative pricing arrangements.

Trade measures have also affected timelines for regulatory submissions and launch sequencing in ways that favor companies with vertically integrated supply chains or robust contingency planning. As a result, strategic responses have included accelerating local production, redesigning packaging and component sourcing to avoid tariff classifications, and pursuing strategic alliances to share manufacturing risk. These approaches help preserve competitive positioning while maintaining continuity of supply for clinicians and patients.

In-depth segmentation synthesis describing product types, drug classes, distribution channels, routes of administration, and end-user cohorts to guide strategic positioning

A precise segmentation lens is essential to understand where clinical value and commercial opportunity intersect across product types, administration routes, distribution pathways, drug classes, and end-user cohorts. Product type segmentation differentiates Biologics from Inhalers, Nebulizers, and Oral Drugs; within Biologics the focus is on antibody therapies such as anti-IgE and anti-IL-5 agents that address eosinophilic and allergic phenotypes, while Inhalers are parsed into Dry Powder Inhalers, Metered Dose Inhalers, and Soft Mist Inhalers, each offering distinct performance characteristics and adherence implications. Nebulizers are subdivided into Jet Nebulizers, Mesh Nebulizers, and Ultrasonic Nebulizers, with usability, particle size control, and portability shaping clinical adoption. Oral Drugs encompass Leukotriene Modifiers, Oral Corticosteroids, and Theophylline, which occupy specific niches based on severity, comorbidity profiles, and tolerability considerations.

Drug class segmentation further clarifies therapy selection drivers by distinguishing Beta Agonists, Combination Therapies, Inhaled Corticosteroids, Leukotriene Modifiers, and Monoclonal Antibodies; each class aligns with particular disease severities and guideline recommendations, influencing prescribing patterns and formulary placement. Distribution channel segmentation highlights variations in access and patient experience across Clinics, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, and the Clinics category includes Home Care Settings and Outpatient Clinics where administration models and reimbursement pathways differ substantially. Route of administration segmentation captures the clinical and logistical trade-offs among Inhalation, Oral, and Parenteral routes; inhalation itself breaks into Aerosol and Powder formats, oral presentations include Syrup Form and Tablet Form, and parenteral delivery is separated into Intravenous and Subcutaneous approaches that affect clinician involvement, monitoring requirements, and patient preference.

End-user segmentation frames demographic-driven demand across Adult, Geriatric, and Pediatric populations; the Geriatric cohort is further divided into 65-74 Years and 75 Plus Years to reflect functional and polypharmacy considerations, while the Pediatric cohort is split into 0-5 Years and 6-12 Years to account for differences in device suitability, dosing constraints, and caregiver support needs. Taken together, these segmentation perspectives enable a nuanced view of product positioning, clinical trial design, reimbursement strategy, and go-to-market execution that aligns with real-world treatment pathways and stakeholder expectations.

Regional intelligence on access, regulatory complexity, and adoption dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets

Regional dynamics shape priorities for product development, regulatory strategy, and commercialization, with distinct opportunities and constraints across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, advanced specialty care networks and widespread availability of biologic therapies support rapid adoption for severe asthma, yet payer sophistication and cost-containment pressures require robust health economic evidence and strategic contracting. As a result, manufacturers prioritizing the Americas tend to emphasize outcomes data, specialty pharmacy partnerships, and patient support models that reduce administrative friction and improve adherence.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse payer systems necessitate tailored market access plans that account for national HTA processes, procurement frameworks, and differing reimbursement criteria. Manufacturers operating across these markets often deploy regional clinical registries and real-world evidence programs to demonstrate value in local contexts, while also investing in pricing strategies adaptable to tendering and reference pricing mechanisms. Capacity constraints in parts of the region can create demand for more robust distribution partnerships and training programs to ensure proper device handling and administration.

The Asia-Pacific region presents a multifaceted picture where rapid healthcare modernization coexists with variable infrastructure and access. In certain markets, high-volume generics producers and a growing biotech sector drive intense competition, while other markets show rising demand for advanced therapies as diagnostic capabilities and specialty care expand. Manufacturers targeting Asia-Pacific frequently balance centralized clinical development with localized regulatory engagement, and they explore tiered product offerings and regional manufacturing hubs to manage cost and improve lead times. Across all regions, localized patient engagement and clinician education remain central to successful adoption.

Strategic competitive overview of innovators, device specialists, generic suppliers, and manufacturing partners shaping product differentiation and market entry

Competitive dynamics in asthma therapeutics are characterized by complementary roles played by innovative biologic developers, legacy inhaler and nebulizer manufacturers, generic and oral therapy suppliers, and emerging device-tech entrants. Innovator companies that specialize in monoclonal antibodies are driving differentiation through biomarker-driven indications, lifecycle strategies, and label expansions into phenotype-specific populations. These firms also invest in companion diagnostics and specialty distribution pathways to optimize patient selection and adherence.

Device manufacturers continue to compete on deliverability, user ergonomics, and integration with digital adherence platforms, forging partnerships with pharmaceutical companies to offer differentiated drug-device combinations. Generic players and manufacturers of oral therapies focus on cost-effectiveness and wide availability, frequently leveraging scale manufacturing and distribution networks to serve primary-care channels. Meanwhile, contract development and manufacturing organizations and device component suppliers are crucial enablers, providing capacity and technical expertise that influence speed to market and the feasibility of onshoring initiatives.

Collectively, company strategies emphasize vertical integration where feasible, strategic partnerships to complement core capabilities, and targeted acquisition to secure device know-how or biologic pipelines. Organizations that combine clinical innovation with strong commercial execution, evidence generation, and supply chain resilience are better positioned to navigate payer scrutiny and to capitalize on evolving clinical guidelines and patient expectations.

Actionable strategic imperatives for manufacturers to align clinical evidence, device integration, supply resilience, and market access for competitive advantage

Industry leaders should adopt a set of pragmatic, actionable strategies that align clinical value with operational resilience and commercial agility. First, prioritize evidence generation that extends beyond randomized trials to include real-world data and patient-reported outcomes; this will strengthen value propositions in payer negotiations and support uptake among clinicians who require proof of effectiveness in routine care. Second, integrate device and digital capabilities early in development to enhance adherence, provide actionable patient data, and create bundled service models that can command premium positioning.

Third, optimize supply chains through geographic diversification, strategic contract manufacturing partnerships, and selective onshoring where tariff exposure or logistics risk is unacceptable. By redesigning sourcing and manufacturing footprints now, companies can reduce vulnerability to trade volatility and preserve launch timelines. Fourth, tailor market access strategies to regional regulatory and reimbursement environments by investing in health economics, outcomes research, and local stakeholder engagement; this ensures that pricing and contracting reflect regional payer priorities and clinical practice.

Finally, pursue targeted collaborations-whether co-development, licensing, or commercial alliances-to access complementary capabilities in biologics, device engineering, or digital health. Such partnerships enable faster market entry, share development risk, and expand therapeutic ecosystems. Executing these recommendations will require cross-functional governance, clear KPIs, and staged investment to align R&D, commercial, and manufacturing objectives with evolving market realities.

Rigorous mixed-methods research approach combining clinical expert interviews, secondary literature synthesis, supply chain mapping, and scenario analysis for robust insights

This analysis synthesizes primary and secondary research disciplines to provide a robust and verifiable evidence base for strategic decisions. Primary research included structured consultations with clinical key opinion leaders in pulmonology and allergy, interviews with commercial executives across therapy and device segments, and discussions with procurement and payer representatives to capture reimbursement priorities and contracting trends. These engagements informed qualitative insights into clinician preferences, patient adherence drivers, and commercial decision-making frameworks.

Secondary research incorporated a comprehensive review of peer-reviewed clinical literature, regulatory guidance documents, and industry publications that describe therapeutic mechanisms, device performance characteristics, and safety considerations. Supply chain mapping and tariff classification analysis were used to identify points of vulnerability and to assess likely mitigation strategies. Triangulation of primary and secondary findings ensured consistency across clinical, commercial, and operational dimensions.

Analytical methods included comparative product positioning analysis, scenario planning for tariff and supply chain disruptions, and segmentation-driven assessment to align product attributes with end-user and distribution channel needs. Quality control measures included cross-validation of interview findings, source verification of regulatory and clinical references, and iterative expert review to refine conclusions. Together, these methods produce a defensible and actionable set of insights for stakeholders planning product development, market access, or strategic investment.

Executive synthesis emphasizing the need for integrated clinical evidence, device innovation, resilient supply chains, and regionally tailored access strategies

In sum, the asthma therapeutics arena presents a complex but navigable set of opportunities that hinge on aligning clinical innovation with pragmatic commercial and operational strategies. Biologic therapies have redefined care for severe phenotypes, while device and digital advancements are improving adherence and supporting new value-based models. However, external pressures such as payer scrutiny and trade-related tariff shifts require adaptive responses in evidence generation, supply chain design, and pricing strategies.

Successful stakeholders will be those who can integrate cross-disciplinary capabilities: developing robust real-world evidence programs, designing user-centric devices, and building resilient manufacturing footprints. Investments in partnerships-whether with device engineers, contract manufacturers, or regional distributors-will accelerate market entry and reduce execution risk. Moreover, tailoring strategies to regional regulatory and reimbursement landscapes will enhance access and commercial performance in diverse markets.

This conclusion underscores the imperative for coordinated action across R&D, commercial, and operations teams to translate scientific advances into sustainable patient impact and commercial returns. Organizations that adopt a proactive stance toward evidence, integration, and resilience will be best positioned to lead in the evolving asthma therapeutics ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Real-world evidence on long-term safety and efficacy of biologic therapies in severe eosinophilic asthma following expanded indications
  • 5.2. Integration of digital inhalers with telehealth platforms to improve adherence and monitoring in pediatric and adult asthma patients
  • 5.3. Development of small molecule CRTh2 receptor antagonists as novel oral therapies for moderate-to-severe asthma management
  • 5.4. Exploration of personalized asthma treatment algorithms incorporating genomic and biomarker profiling data for targeted biologic selection
  • 5.5. Advances in triple combination inhalers delivering ICS, LABA, and LAMA therapies for improved control in uncontrolled asthma populations
  • 5.6. Regulatory impact of recent FDA and EMA label expansions for tezepelumab and dupilumab on global asthma treatment strategies
  • 5.7. Emergence of anti-TSLP and anti-IL-25 pipeline candidates and their potential to redefine severe asthma therapeutic options

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Asthma Therapeutics Market, by Product Type

  • 8.1. Biologics
    • 8.1.1. Anti-Ige
    • 8.1.2. Anti-Il5
  • 8.2. Inhalers
    • 8.2.1. Dry Powder Inhalers
    • 8.2.2. Metered Dose Inhalers
    • 8.2.3. Soft Mist Inhalers
  • 8.3. Nebulizers
    • 8.3.1. Jet Nebulizers
    • 8.3.2. Mesh Nebulizers
    • 8.3.3. Ultrasonic Nebulizers
  • 8.4. Oral Drugs
    • 8.4.1. Leukotriene Modifiers
    • 8.4.2. Oral Corticosteroids
    • 8.4.3. Theophylline

9. Asthma Therapeutics Market, by Drug Class

  • 9.1. Beta Agonists
  • 9.2. Combination Therapies
  • 9.3. Inhaled Corticosteroids
  • 9.4. Leukotriene Modifiers
  • 9.5. Monoclonal Antibodies

10. Asthma Therapeutics Market, by Distribution Channel

  • 10.1. Clinics
    • 10.1.1. Home Care Settings
    • 10.1.2. Outpatient Clinics
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Asthma Therapeutics Market, by Route Of Administration

  • 11.1. Inhalation
    • 11.1.1. Aerosol
    • 11.1.2. Powder
  • 11.2. Oral
    • 11.2.1. Syrup Form
    • 11.2.2. Tablet Form
  • 11.3. Parenteral
    • 11.3.1. Intravenous
    • 11.3.2. Subcutaneous

12. Asthma Therapeutics Market, by End User

  • 12.1. Adult
  • 12.2. Geriatric
    • 12.2.1. 65-74 Years
    • 12.2.2. 75 Plus Years
  • 12.3. Pediatric
    • 12.3.1. 0-5 Years
    • 12.3.2. 6-12 Years

13. Asthma Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Asthma Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Asthma Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. AstraZeneca PLC
    • 16.3.3. Teva Pharmaceutical Industries Limited
    • 16.3.4. Novartis AG
    • 16.3.5. Sanofi S.A.
    • 16.3.6. Boehringer Ingelheim International GmbH
    • 16.3.7. Viatris Inc.
    • 16.3.8. Sunovion Pharmaceuticals Inc.
    • 16.3.9. Chiesi Farmaceutici S.p.A.
    • 16.3.10. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ASTHMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-IL5, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THEOPHYLLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY AEROSOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SYRUP FORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY TABLET FORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 75 PLUS YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 0-5 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY 6-12 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY GERIATRIC, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 326. NORTH AMERICA ASTHMA THERAPEU